Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

Immune checkpoint inhibitors (ICIs) are novel immunotherapy-based drugs that have become increasingly popular in the treatment of lung cancer. Researchers have recognized ocular immune-related adverse events (irAEs) secondary to ICIs because of their vision-threatening characteristics. However, they...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lin, Wei, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421677/
https://www.ncbi.nlm.nih.gov/pubmed/34504488
http://dx.doi.org/10.3389/fimmu.2021.701951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421677/
https://www.ncbi.nlm.nih.gov/pubmed/34504488
http://dx.doi.org/10.3389/fimmu.2021.701951

Ejemplares similares